Display options
Cite
Kumar A, Sharma D, Aggarwal ML, et al. Cancer/testis antigens as molecular drug targets using network pharmacology. Tumour Biol. 2016;doi: 10.1007/s13277-016-5333-2.
Kumar, A., Sharma, D., Aggarwal, M. L., Chacko, K. M., & Bhatt, T. K. (2016). Cancer/testis antigens as molecular drug targets using network pharmacology. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, . https://doi.org/10.1007/s13277-016-5333-2
Kumar, Anuj, et al. "Cancer/testis antigens as molecular drug targets using network pharmacology." Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine vol. (2016). doi: https://doi.org/10.1007/s13277-016-5333-2
Kumar A, Sharma D, Aggarwal ML, Chacko KM, Bhatt TK. Cancer/testis antigens as molecular drug targets using network pharmacology. Tumour Biol. 2016 Oct 05; doi: 10.1007/s13277-016-5333-2. Epub 2016 Oct 05. PMID: 27709548.
Copy Download .nbib Format: NLM
Share it on

Tumour Biol. 2016 Oct 05; doi: 10.1007/s13277-016-5333-2. Epub 2016 Oct 05.

Cancer/testis antigens as molecular drug targets using network pharmacology.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Anuj Kumar, Drista Sharma, M L Aggarwal, K M Chacko, Tarun Kumar Bhatt

Affiliations

  1. Shriram Institute for Industrial Research, 19, University Road Delhi, Delhi, 110 007, India. [email protected].
  2. Department of Biotechnology, Central University of Rajasthan, NH-8, Bandarsindri, Rajasthan, 305801, India.
  3. Shriram Institute for Industrial Research, 19, University Road Delhi, Delhi, 110 007, India.
  4. Department of Biotechnology, Central University of Rajasthan, NH-8, Bandarsindri, Rajasthan, 305801, India. [email protected].

PMID: 27709548 DOI: 10.1007/s13277-016-5333-2

Abstract

Present chemotherapeutic drugs have limited efficacy and severe side effects. Considering the complexity of cancer, an effective strategy is necessary to discover multiple new drug targets. Cancer/testis antigens are vital for cancer cell progression. We have performed a computational network analysis of cancer/testis antigens and assessed these antigens as drug targets. During this analysis, protein interaction network of 700 human CT antigens was investigated. CT antigen network consisted of eight independent components. Four major hubs and two minor hubs were identified that play nodal role in the flow of information across the largest network. We have predicted 30 potential drug targets by analysing several topological parameters such as betweenness centrality, cluster coefficient and probable protein complexes. Structural and functional roles of potential drug targets have also been anatomized. Analysis of the CT antigen network enables us to pinpoint a set of candidate proteins that if targeted could be detrimental for cancerous cell without affecting any normal cell. The list of putative proteins is a starting point for experimental validation and may help further in the discovery of new anticancer drug targets.

Keywords: Anticancer targets; Cancer; Cancer/testis antigens; Protein interaction network

References

  1. J Urol. 2002 Feb;167(2 Pt 2):928-32; discussion 933 - PubMed
  2. Proc Natl Acad Sci U S A. 2007 May 22;104(21):8685-90 - PubMed
  3. Expert Rev Vaccines. 2011 Nov;10(11):1569-83 - PubMed
  4. Cancer Immun. 2008 Aug 28;8:13 - PubMed
  5. Expert Opin Biol Ther. 2006 Apr;6(4):379-89 - PubMed
  6. Cancer Immun. 2008 Apr 22;8:7 - PubMed
  7. PLoS Comput Biol. 2009 Dec;5(12):e1000601 - PubMed
  8. BMC Bioinformatics. 2003 Jan 13;4:2 - PubMed
  9. Front Cell Infect Microbiol. 2016 Jan 11;5:102 - PubMed
  10. Cancer Cell Int. 2005 Feb 16;5(1):4 - PubMed
  11. Cancer Immun. 2007 Dec 21;7:21 - PubMed
  12. Cancer Immun. 2006 Dec 01;6:12 - PubMed
  13. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  14. J Clin Oncol. 2000 Sep;18(17):3068-77 - PubMed
  15. Oncol Rep. 2004 Mar;11(3):559-95 - PubMed
  16. Mol Cell Biol. 2015 Oct;35(19):3436-45 - PubMed
  17. J Biol Chem. 2015 Dec 4;290(49):29652-62 - PubMed
  18. Cancer Res. 1999 Dec 15;59(24):6197-204 - PubMed
  19. Nat Chem Biol. 2008 Nov;4(11):682-90 - PubMed
  20. BMC Bioinformatics. 2010 Sep 27;11:484 - PubMed
  21. Cancer Immun. 2008 Feb 01;8:2 - PubMed
  22. Cancer Sci. 2009 Nov;100(11):2014-21 - PubMed
  23. Cancer Res. 1991 Feb 15;51(4):1078-85 - PubMed
  24. Nat Rev Clin Oncol. 2010 Dec;7(12):718-24 - PubMed

Publication Types